 |
 |
© Anna Surinyach |
At this year's 63rd World Health Assembly, Médecins Sans Frontières (MSF) and Drugs for Neglected Disease Initiative (DNDi) called for Member States to include the integration of treatment and diagnosis at primary healthcare level and increased efforts in research and development in resolution, 'Chagas Disease: Control and Elimination'.
Related Links
The outcomes of the 63rd WHA on Chagas disease (1 June 2010)
Press Release "World Health Assembly: MSF and DNDi call for a more rounded resolution on Chagas disease" (17 May 2010)
MSF's Letter to WHA Delegates (22 April 2010)
More information on Chagas disease
|
Although WHO recently reported that the number of new cases of sleeping sickness had dropped to 50-year low, MSF cautions that the problem could be larger than it seems due to remote and neglected populations vulnerable to the disease. Read more |
|
Fighting kala azar in the Indian state of Bihar is challenging due to high cost of treatment that makes it difficult for widespread use. Hear the stories of many patients, doctors, and government officials as they discuss their experience treating this neglected disease. read more |
IN THE NEWS
"As doctors, we cannot simply choose which diseases to treat. Sleeping sickness and visceral leishmaniasis are both 100 percent lethal without treatment, taking the lives of more than 100,000 people each year in sub-Saharan Africa and South Asia...."
Incoming President of MSF's International Council Dr. Unni Karunakara and Dr. Bernard Pecoul, executive director of the Drugs for Neglected Diseases initiative call on the Obama administration to do more for neglected diseases with its Global Health Initiative.
To read the full text, click here
|
MSF & Measles MSF urged member states at the 63rd World Health Assembly to give WHO the additional resources necessary to assist countries in outbreak response and to ensure continuous support to measles control programmes. Read more |
Watch this film on kala azar, a disease that effects who doctors describe as "the poorest of the poor". Learn more about who it effects and how it can be treated. |
|
MSF and Malaria To find out about MSF's work with malaria and current issues surrounding the launch of a new global subsidy to massively reduce the price of effective malaria treatment click here |
|
Leishmaniasis (Kala-azar) is largely unknown, although it affects over 12 million people worldwide. Cheaper, safer and more practical drugs are needed to improve patients’ access to treatment. Read about a Kenyan mother seeking treatment for her son click here |
